Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3% – Time to Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) were up 10.3% during trading on Thursday . The stock traded as high as $52.25 and last traded at $52.9810. Approximately 293,962 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 797,129 shares. The stock had previously closed at $48.03.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Wedbush reiterated an “outperform” rating and set a $46.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Truist Financial boosted their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $64.43.

Dianthus Therapeutics Price Performance

The stock’s 50 day simple moving average is $42.13 and its two-hundred day simple moving average is $33.55. The company has a market capitalization of $2.26 billion, a P/E ratio of -15.16 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 216,538 shares of company stock valued at $8,283,175. 8.15% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Parkside Financial Bank & Trust raised its stake in shares of Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $64,000. Tower Research Capital LLC TRC boosted its position in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth $94,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.